These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


315 related items for PubMed ID: 29577852

  • 21. Biowaiver monographs for immediate release solid oral dosage forms: piroxicam.
    Shohin IE, Kulinich JI, Ramenskaya GV, Abrahamsson B, Kopp S, Langguth P, Polli JE, Shah VP, Groot DW, Barends DM, Dressman JB.
    J Pharm Sci; 2014 Feb; 103(2):367-77. PubMed ID: 24301077
    [Abstract] [Full Text] [Related]

  • 22. Influence of drug release properties of conventional solid dosage forms on the systemic exposure of highly soluble drugs.
    Yu LX, Ellison CD, Conner DP, Lesko LJ, Hussain AS.
    AAPS PharmSci; 2001 Feb; 3(3):E24. PubMed ID: 11741275
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Development and application of a biorelevant dissolution method using USP apparatus 4 in early phase formulation development.
    Fang JB, Robertson VK, Rawat A, Flick T, Tang ZJ, Cauchon NS, McElvain JS.
    Mol Pharm; 2010 Oct 04; 7(5):1466-77. PubMed ID: 20701327
    [Abstract] [Full Text] [Related]

  • 31. Developing dissolution testing methodologies for extended-release oral dosage forms with supersaturating properties. Case example: Solid dispersion matrix of indomethacin.
    Tajiri T, Morita S, Sakamoto R, Mimura H, Ozaki Y, Reppas C, Kitamura S.
    Int J Pharm; 2015 Jul 25; 490(1-2):368-74. PubMed ID: 26022889
    [Abstract] [Full Text] [Related]

  • 32. Miniaturized approach for excipient selection during the development of oral solid dosage form.
    Raijada D, Müllertz A, Cornett C, Munk T, Sonnergaard J, Rantanen J.
    J Pharm Sci; 2014 Mar 25; 103(3):900-8. PubMed ID: 24436033
    [Abstract] [Full Text] [Related]

  • 33. Is the use of a 200 ml vessel suitable for dissolution of low dose drug products?
    Crail DJ, Tunis A, Dansereau R.
    Int J Pharm; 2004 Jan 09; 269(1):203-9. PubMed ID: 14698592
    [Abstract] [Full Text] [Related]

  • 34. Predicting in vivo absorption behavior of oral modified release dosage forms containing pH-dependent poorly soluble drugs using a novel pH-adjusted biphasic in vitro dissolution test.
    Heigoldt U, Sommer F, Daniels R, Wagner KG.
    Eur J Pharm Biopharm; 2010 Sep 09; 76(1):105-11. PubMed ID: 20472059
    [Abstract] [Full Text] [Related]

  • 35. Oral controlled release dosage forms: dissolution versus diffusion.
    Bermejo M, Sanchez-Dengra B, Gonzalez-Alvarez M, Gonzalez-Alvarez I.
    Expert Opin Drug Deliv; 2020 Jun 09; 17(6):791-803. PubMed ID: 32248713
    [Abstract] [Full Text] [Related]

  • 36. Statistical Considerations Concerning Dissimilar Regulatory Requirements for Dissolution Similarity Assessment. The Example of Immediate-Release Dosage Forms.
    Jasińska-Stroschein M, Kurczewska U, Orszulak-Michalak D.
    J Pharm Sci; 2017 May 09; 106(5):1275-1284. PubMed ID: 28088455
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Can dosage form-dependent food effects be predicted using biorelevant dissolution tests? Case example extended release nifedipine.
    Andreas CJ, Tomaszewska I, Muenster U, van der Mey D, Mueck W, Dressman JB.
    Eur J Pharm Biopharm; 2016 Aug 09; 105():193-202. PubMed ID: 27322002
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 16.